Search
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in
Synonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamideCarfilzomib
go.drugbank.com/drugs/DB08889ApprovedInvestigationalCarfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. … FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Daraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigational[L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common … Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma.
Acetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalIt is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications. … Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in
Products: Miochol E, MIOCHOL ESitaxentan
go.drugbank.com/drugs/DB06268ApprovedWithdrawnIn 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity. … Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.
Cortisone acetate
go.drugbank.com/drugs/DB01380ApprovedInvestigationalCortisone acetate was first isolate in 1935 and became more widely researched in 1949. … [A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107]
Promethazine
go.drugbank.com/drugs/DB01069ApprovedInvestigationalPromethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946.
Mixtures: COPHADYL-E COUGH LINCTUSSynonyms: N,N,α-trimethyl-10H-phenothiazine-10-ethanamine, N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamineRelebactam
go.drugbank.com/drugs/DB12377ApprovedInvestigationalinfections in adults. … Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to [avibactam].
Safflower oil
go.drugbank.com/drugs/DB09446ApprovedInvestigationalWithdrawnSafflower oil is approved for use as an indirect additive in food contact substances and is readily available as a food ingredient. … acid [A32677, A32679], depending on the flower type.
Categories: Complex Mixtures